FREE 2-DAY SHIPPING ON ORDERS $200+

Blog

Retatrutide vs VK2735: Results, Side Effects and the Race to Approval (2026)

A row of glass diffusion cells clamped in a water bath on a bright lab bench

VK2735 is Viking Therapeutics’ run at tirzepatide’s formula: the same two receptors, GLP-1 and GIP, in a once-weekly shot, with the same molecule also being made into a daily tablet. Retatrutide is Lilly’s step past that pair, adding glucagon as a third signal.

VK2735’s early numbers move fast: 14.7% of starting weight gone by week 13. Its longest result, though, comes from a single group at 33 weeks, while retatrutide’s Phase 3 trials have run to 80 and 104 weeks and reached 28.3% at 80. No trial has tested one against the other, so the comparison below lines up separate studies at the closest matching weeks and says who was in each.

Simms Research carries one of the two: Retatrutide (GLP-3), sold in four sizes with a posted lab report. VK2735 isn’t stocked.

Retatrutide vs VK2735: the main differences

The gap comes down to one receptor, well over a year more trial data and a place in the approval queue. Every retatrutide figure below is its 12mg top dose; VK2735’s are its highest doses tested.

PointRetatrutideVK2735
ReceptorsGIP, GLP-1 and glucagonGLP-1 and GIP
DeveloperEli LillyViking Therapeutics
Forms in trialsWeekly injectionWeekly injection; daily tablet
Weekly doses in Phase 34mg, 9mg, 12mg7.5mg, 12.5mg, 17.5mg
Half-lifeAbout 6 daysAbout 7 to 10 days
Weight loss near 5 months17.5% at 24 weeksAbout 16% to 19% at 21 weeks
Longest result28.3% at 80 weeksAbout 22% at 33 weeks
Stopped over side effects, top dose16% over 48 weeks20% over 13 weeks
Where it standsMain Phase 3 results in; FDA filing early 2027Phase 3 under way; ends in 2027
Stocked by Simms ResearchYes, four sizesNo

The side-effect row sets the two Phase 2 trials against each other, the closest like-for-like pair. In retatrutide’s 80-week Phase 3, with a gentler climb to 12mg, 11.3% stopped over side effects against 4.9% on placebo.

What is VK2735?

A once-weekly injectable peptide from Viking Therapeutics, a drug developer in San Diego, built to hit both the GLP-1 and the GIP receptor. Viking chose it from a series of dual agonists it designed itself, and first gave it to people in 2022.

Viking hasn’t published its amino acid sequence or molecular weight, so VK2735’s structure is not public the way retatrutide’s is (39 amino acids, 4,731 g/mol, on a GIP backbone). The company is also taking the same molecule forward as a once-daily tablet, a form tirzepatide doesn’t come in.

Retatrutide’s own background, from Lilly’s lab to the clinic, is in What Is Retatrutide? How the Reta Peptide Works.

VK2735 half-life

About 170 to 250 hours after a single injection, roughly 7 to 10 days, with the peak level arriving three to four days after the dose. Retatrutide’s is about 6 days, as the retatrutide half-life guide sets out, and both are dosed once a week in their trials. The longer tail is what lets Viking test a shot every other week, or once a month, after the weight has come off.

Two small groups of capped glass vials of clear liquid on a steel lab bench, a closed notebook between them and ball-and-stick molecule models behind

Retatrutide vs VK2735 mechanism: what glucagon adds

Both drugs turn appetite down through GLP-1 and GIP. Retatrutide adds the glucagon receptor, which turns up the body’s energy use and pulls fat from liver cells.

The liver is where the third receptor shows most. Retatrutide 12mg cut liver fat by 82.4% by week 24 in a Phase 2 substudy (Sanyal, Nature Medicine, 2024); Retatrutide for Fatty Liver has the full results and the trial now under way. VK2735’s liver figures stop at its first human study, where four weekly doses lowered liver fat by up to 47.3% in 28 days.

For weight, glucagon’s share is easier to argue than to measure, because no trial has compared retatrutide with VK2735. The nearest thing is TRIUMPH-5, where Lilly is giving 800 people either retatrutide or tirzepatide. Tirzepatide works on the same pair as VK2735, so that trial prices the third receptor more directly than anything Viking will run.

Automated liquid-handling robot inside a clear enclosure lowering a row of pipette tips over white sample plates, beside racks of tips, in a bright lab

VK2735 trial results

Up to 14.7% at 13 weeks, about 16% to 19% at 21 weeks, and about 22% at 33 weeks for one group on 17.5mg, all from studies of 33 weeks or less.

VENTURE, the injection’s Phase 2, put 176 adults on 2.5mg, 5mg, 10mg or 15mg a week, or placebo, for 13 weeks. Everyone had a BMI of at least 30, or 27 alongside a condition such as high blood pressure or sleep apnea; diabetes ruled people out. Weight fell 9.1% on the lowest dose and 14.7% on the highest, against 1.7% on placebo, and 41.5% of the 15mg group lost at least 15% (Bays, Obesity, 2026). Of those on VK2735 who started with prediabetes, 78% had normal blood sugar by the last week.

A second study pushed doses higher and stretched the clock. Its 180 adults spent 21 weeks on 15mg to 22.5mg a week, climbing every two weeks rather than every three, and lost about 16% to 19%; 65% passed 15% and 32% passed 20%. Moved to a shot every other week or once a month for 12 more weeks, they held on to 82% to 97% of that loss, against 61% for those switched to placebo. The group kept on 17.5mg weekly reached about 22% by week 33 and was still losing (Viking, October 2026).

VK2735 tablet results

In the tablet’s Phase 2, 280 adults took 15mg to 120mg a day for 13 weeks. On 120mg, weight fell 12.2%, against 1.3% on placebo, and 80% of that group passed 10%. The price was tolerability: 28% of people on the tablet stopped early against 18% on placebo, 38% at 120mg, and vomiting hit 26% against 10%. Its Phase 3 uses lower daily doses, 27.5mg to 55mg.

Retatrutide has no tablet in development; Is There a Retatrutide Pill? covers why it stays a weekly injection.

Retatrutide vs VK2735 weight loss

Close at five months. After that, only retatrutide has the results.

The two Phase 2 trials drew from the same pool: adults with obesity, or overweight plus a related condition, and none with diabetes. Around the five-month mark, VK2735’s higher doses stood at about 16% to 19% in week 21, and retatrutide 12mg at 17.5% in week 24 (Jastreboff, New England Journal of Medicine, 2023). VK2735 also climbs steeply early on, with 14.7% already gone at week 13.

Beyond that, the trials stop lining up. VK2735’s furthest point is one group at about 22% after 33 weeks. Retatrutide 12mg went on to 24.2% at 48 weeks, 28.3% at 80 weeks in TRIUMPH-1, and 30.3% at 104 weeks for people who started with a BMI of 35 or more.

Who took part moves these numbers as well. VENTURE’s group was about three-quarters women and started near 102 kg; retatrutide’s Phase 2 was about half women and started near 108 kg. VK2735’s 21-week and 33-week figures are topline results that haven’t yet appeared in a journal. Retatrutide’s results at every checkpoint from 24 weeks to two years are gathered in How Long Does Retatrutide Take to Work?

White benchtop centrifuge with its lid open on a pale blue lab bench by a window, beside a rack of capped tubes of clear liquid

VK2735 vs retatrutide side effects

Stomach effects first on both, heaviest in the opening weeks and mostly mild to moderate. VK2735’s short Phase 2 lost a larger share of its top-dose group than retatrutide’s year-long one.

Nausea hit 63% of the VK2735 15mg group, against 20% on placebo, with 29% vomiting against none and 29% constipation against 11%; 20% of the group stopped over side effects, and nobody on placebo did. That group began on 5mg while the others began on 2.5mg, and its nausea peaked in week one. Starting below 5mg is now built into Phase 3, and in the maintenance study, stomach complaints during the every-other-week and monthly phase ran close to placebo.

On retatrutide 12mg, nausea reached 45% against 11% across the 48 weeks of its Phase 2, and 16% of that group stopped over side effects. TRIUMPH-1’s slower climb cut the stopping rate to 11.3% over 80 weeks, against 4.9% on placebo, with nausea at 42.4% against 14.8%.

One effect belongs to retatrutide so far: dysesthesia, a tingling or touch-sensitive feeling in the skin, in up to 12.5% of people on the top dose against 0.9% on placebo, usually mild. Retatrutide Side Effects by Dose gives every rate at each dose.

VK2735 vs tirzepatide

The same two receptors, which makes tirzepatide VK2735’s nearest rival. Tirzepatide is approved and sold as Zepbound and Mounjaro; VK2735 aims to match it with a longer-lasting dose and a tablet.

Their closest numbers sit near each other. Adults on tirzepatide’s highest tolerated dose lost 20.9% across the 36-week open-label start of SURMOUNT-4 (Aronne, JAMA, 2024); VK2735’s 17.5mg group was at about 22% after 33 weeks. Neither has been tested against the other, so VANQUISH’s 78-week results are the next real marker.

Tirzepatide’s half-life is about 5 days, VK2735’s about 7 to 10. Viking’s wager is that the extra days let people keep weight off on fewer shots, which its maintenance study and the Phase 3 extensions are built to test.

Tirzepatide (GLP-2) is the dual agonist Simms Research stocks, in four vial sizes from 10mg up to 60mg, $65 to $186. Where the third receptor takes retatrutide past tirzepatide is set out in Retatrutide vs Tirzepatide: Which Is Better, Dose for Dose?

VK2735 Phase 3 and FDA approval

VK2735’s Phase 3 trials are due to finish in 2027. Retatrutide has six Phase 3 results in hand and reaches the FDA first, with Lilly planning its filing for the first quarter of 2027.

Viking’s injection program, VANQUISH, is two 78-week trials of 7.5mg, 12.5mg or 17.5mg a week against placebo. VANQUISH-1 signed up about 4,500 adults without diabetes in roughly five months and was full by November 2025; VANQUISH-2, about 1,000 adults with type 2 diabetes, filled in March 2026. Both are set to end in 2027, and 52-week extensions starting early that year will test a shot every other week and once a month, with results in 2028.

The tablet followed in October 2026 with SUNRISE-1 and SUNRISE-2, 68 weeks each and 560 adults apiece, on 27.5mg, 35mg or 55mg a day.

Retatrutide’s Phase 3 results arrived between December 2025 and October 2026, across obesity, type 2 diabetes, sleep apnea and knee pain. The months between that filing and a decision are mapped in When Will Retatrutide Be FDA Approved?

Is VK2735 FDA approved?

No. No regulator anywhere has approved it, and an application would follow the VANQUISH results. Retatrutide isn’t approved yet either, but its filing comes first.

Is VK2735 better than retatrutide?

Not on the results published so far. At about five months the two are level; past that, retatrutide has 80 and 104 weeks of Phase 3 results, and VK2735 has a single group followed to 33 weeks.

VK2735 brings real strengths: a dose that lasts longer, weight held on monthly shots in its maintenance study, a tablet of the same molecule, and Phase 3 programs enrolling more than 6,000 people. Retatrutide answers with the size and length of its results, the liver-fat effect glucagon adds, and a filing date.

For research now, only one of the two is on the shelf at Simms Research. The 10mg vial of Retatrutide (GLP-3) is $84 and the 60mg $259, with 20mg at $129 and 30mg at $159; per mg, that runs from $8.40 down to $4.32.

Three vials tested from its July 16, 2026 batch measured 10.68mg net against a 10mg label. Purity came in at 99.611%, RP-HPLC and LC-MS confirmed it as retatrutide, endotoxins passed, heavy metals were negative and nothing grew in the microbial test. The retatrutide lab results list every field; the retatrutide dosage chart has the weekly step-up, and the retatrutide calculator gives the syringe reading for any vial and dose.

Frequently asked questions

Can you buy VK2735?

Not as a prescription; it is still in Phase 3. Simms Research doesn’t carry it. In the same family it stocks tirzepatide, which works on VK2735’s two receptors, and retatrutide, which adds glucagon.

Is VK2735 the same as tirzepatide?

No. They share two receptors, but VK2735 is a separate molecule from a different company, its dose lasts a few days longer, and its sequence hasn’t been made public.

Can you take VK2735 and retatrutide together?

They have never been studied together, and the overlap is large: VK2735’s two receptors are two of retatrutide’s three.

Who makes VK2735?

Viking Therapeutics, a San Diego company listed on the Nasdaq. It held $960 million in cash and investments at the end of September 2026, with VANQUISH and SUNRISE both running.

Is Simms Research legit?

It’s a US research supplier with its retatrutide certificate posted in full, same-day dispatch on orders in by 5PM Eastern, and a Free Delivery Guarantee that replaces or refunds a parcel that goes missing, is stolen once scanned as delivered, or arrives damaged. Questions reach a person at support@simmsresearch.com or on 855-592-8507 on weekdays from 9AM to 5PM Eastern.

Does this page use a discount code?

No. This page carries no discount code and no affiliate link, and the vial prices quoted are regular prices.

Keep exploring

Verify the underlying batch data

Compare published methods and results, then open the source certificate for the batch you are evaluating.

Browse lab results